Study of 5 Volatile Organic Compounds in Exhaled Breath in Chronic Obstructive Pulmonary Disease

Jareño-Esteban, José Javier; Muñoz-Lucas, M. Ángeles; Gómez-Martín, Óscar; Utrilla-Trigo, Sergio; Gutiérrez-Ortega, Carlos; Ros, Antonio Aguilar; Collado-Yurrita, Luis; Callol-Sánchez, Luis Miguel

doi:10.1016/j.arbr.2017.03.007

Cited by 19 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 139 studies were included in the present review. From the total of 60 cross-sectional clinical studies selected [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 ], 33 ...…”

Section: Statistics Of Included Studiesmentioning

confidence: 99%

“…Of the selected clinical studies, thirty-two of them reported that they used mixed expired breath [ 13 , 17 , 19 , 21 , 33 , 34 , 36 , 38 , 41 , 42 , 43 , 45 , 46 , 54 , 59 , 60 , 61 , 62 , 64 , 66 , 67 , 68 , 69 , 71 , 72 , 73 , 75 , 76 , 78 , 80 , 83 , 85 ] (consisting normally in a mixture of gaseous breath, that also includes the volatile components) collected by simple expiration in bags, tubes with absorbent materials or directly into the used instrumentation (as in the case of E-noses, for example). A total of twenty-two of them reported the use of alveolar breath [ 14 , 15 , 16 , 18 , 22 , 32 , 35 , 37 , 44 , 48 , 56 , 57 , 58 , 65 , 70 , 74 , 77 , 79 , 81 , 82 , 84 , 86 ] (collected at the appropriate time by monitoring CO 2 levels as a function of time). Three stud...…”

Section: Statistics Of Included Studiesmentioning

confidence: 99%

“…The COPD diagnosis is almost similar to that of asthma, while a VOC analysis is also possible. COPD was investigated by GC-MS in six studies included in this review [ 14 , 19 , 54 , 63 , 79 , 81 ]. Phillips and co-authors involved 119 patients with COPD and 63 controls in their study.…”

Section: Diagnosis Of Investigated Respiratory Diseasesmentioning

confidence: 99%

“…Aldehydes are also associated with oxidative stress and inflammatory processes [ 4 ]. Hexanal, heptanal and nonanal, which are formed by the peroxidation of ω 3 and ω 6 fatty acids [ 59 ], have been reported as markers of asthma, lung cancer and COPD [ 36 , 56 , 75 , 76 , 78 , 79 ]. Aldehyde concentrations are known to be affected by age (e.g., pentane may indicate higher metabolic demands of young adults) and smoking history [ 4 ].…”

Section: The Origin Of Vocs Related To the Investigated Diseases Amentioning

confidence: 99%

See 3 more Smart Citations

Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

Rațiu

Ligor

Bocoş-Binţinţan

et al. 2020

JCM

116

View full text Add to dashboard Cite

Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of death worldwide by cancer is that of the lung, which, in large part, is a result of the disease often not being detected until a late stage. Although COPD and asthma are conditions with considerably lower mortality, they are extremely distressful to people and involve high healthcare overheads. Moreover, for these diseases, diagnostic methods are not only costly but are also invasive, thereby adding to people’s stress. It has been appreciated for many decades that the analysis of trace volatile organic compounds (VOCs) in exhaled breath could potentially provide cheaper, rapid, and non-invasive screening procedures to diagnose and monitor the above diseases of the lung. However, after decades of research associated with breath biomarker discovery, no breath VOC tests are clinically available. Reasons for this include the little consensus as to which breath volatiles (or pattern of volatiles) can be used to discriminate people with lung diseases, and our limited understanding of the biological origin of the identified VOCs. Lung disease diagnosis using breath VOCs is challenging. Nevertheless, the numerous studies of breath volatiles and lung disease provide guidance as to what volatiles need further investigation for use in differential diagnosis, highlight the urgent need for non-invasive clinical breath tests, illustrate the way forward for future studies, and provide significant guidance to achieve the goal of developing non-invasive diagnostic tests for lung disease. This review provides an overview of these issues from evaluating key studies that have been undertaken in the years 2010–2019, in order to present objective and comprehensive updated information that presents the progress that has been made in this field. The potential of this approach is highlighted, while strengths, weaknesses, opportunities, and threats are discussed. This review will be of interest to chemists, biologists, medical doctors and researchers involved in the development of analytical instruments for breath diagnosis.

show abstract

Section: Statistics Of Included Studiesmentioning

confidence: 99%

Section: Statistics Of Included Studiesmentioning

confidence: 99%

Section: Diagnosis Of Investigated Respiratory Diseasesmentioning

confidence: 99%

Section: The Origin Of Vocs Related To the Investigated Diseases Amentioning

confidence: 99%

See 2 more Smart Citations

Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

Rațiu

Ligor

Bocoş-Binţinţan

et al. 2020

JCM

116

View full text Add to dashboard Cite

show abstract

“…A study by Van Berkel et al 20 demonstrated the ability to distinguish COPD subjects from controls solely based on the presence of VOCs in breath, suggesting that analysis of VOC might be highly relevant for diagnosis of COPD. This established the basis of further studies of VOC in COPD21–25 recommending larger studies for validation.…”

Section: Introductionmentioning

confidence: 82%

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study

et al. 2019

View full text Add to dashboard Cite

IntroductionPatients presenting with acute undifferentiated breathlessness are commonly encountered in admissions units across the UK. Existing blood biomarkers have clinical utility in distinguishing patients with single organ pathologies but have poor discriminatory power in multifactorial presentations. Evaluation of volatile organic compounds (VOCs) in exhaled breath offers the potential to develop biomarkers of disease states that underpin acute cardiorespiratory breathlessness, owing to their proximity to the cardiorespiratory system. To date, there has been no systematic evaluation of VOC in acute cardiorespiratory breathlessness. The proposed study will seek to use both offline and online VOC technologies to evaluate the predictive value of VOC in identifying common conditions that present with acute cardiorespiratory breathlessness.Methods and analysisA prospective real-world observational study carried out across three acute admissions units within Leicestershire. Participants with self-reported acute breathlessness, with a confirmed primary diagnosis of either acute heart failure, community-acquired pneumonia and acute exacerbation of asthma or chronic obstructive pulmonary disease will be recruited within 24 hours of admission. Additionally, school-age children admitted with severe asthma will be evaluated. All participants will undergo breath sampling on admission and on recovery following discharge. A range of online technologies including: proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry and offline technologies including gas chromatography mass spectroscopy and comprehensive two-dimensional gas chromatography-mass spectrometry will be used for VOC discovery and replication. For offline technologies, a standardised CE-marked breath sampling device (ReCIVA) will be used. All recruited participants will be characterised using existing blood biomarkers including C reactive protein, brain-derived natriuretic peptide, troponin-I and blood eosinophil levels and further evaluated using a range of standardised questionnaires, lung function testing, sputum cell counts and other diagnostic tests pertinent to acute disease.Ethics and disseminationThe National Research Ethics Service Committee East Midlands has approved the study protocol (REC number: 16/LO/1747). Integrated Research Approval System (IRAS) 198921. Findings will be presented at academic conferences and published in peer-reviewed scientific journals. Dissemination will be facilitated via a partnership with the East Midlands Academic Health Sciences Network and via interaction with all UK-funded Medical Research Council and Engineering and Physical Sciences Research Council molecular pathology nodes.Trial registration numberNCT03672994.

show abstract

Breathprinting-Based Diagnosis: Case Study: Respiratory Diseases

2019

View full text Add to dashboard Cite

Study of 5 Volatile Organic Compounds in Exhaled Breath in Chronic Obstructive Pulmonary Disease

Cited by 19 publications

References 16 publications

Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study

Breathprinting-Based Diagnosis: Case Study: Respiratory Diseases

Contact Info

Product

Resources

About